Horizon Flexible Income ETF (FLXN)

Flexion Therapeutics, Inc. (FLXN) is a biopharmaceutical company that develops and commercializes innovative therapies for the treatment of musculoskeletal conditions. The company's products and services include Zilretta, a non-opioid treatment for osteoarthritis knee pain, and FX301, a sustained-release local anesthetic for postoperative pain. Flexion Therapeutics is headquartered in Burlington, Massachusetts.

Flexion Therapeutics' products have the potential to address significant unmet medical needs in the treatment of musculoskeletal conditions. The company has a strong pipeline of product candidates, and has formed strategic partnerships with a range of organizations to expand the reach of its products and services.

The biopharmaceutical industry is subject to various risks, including regulatory risks and competition from other companies. However, Flexion Therapeutics' experienced management team, strategic partnerships, and strong pipeline of product candidates should position it well for continued success in the future.

Flexion Therapeutics' stock is listed on the NASDAQ stock exchange under the ticker symbol FLXN.